Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Talquetamab + teclistamab in patients with drug-resistant true extramedullary myeloma show ORR 79%, PFS at 12 months was 61%, OS was 74%; common grade 3/4 AEs were heme in 76% and infection in 31%; 10 deaths (5 treatment, 5 infection).”
Title: Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab
Authors: Shaji Kumar, María-Victoria Mateos, Jing Christine Ye, Shebli Atrash, Hila Magen, Hang Quach, Michael P. Chu, Suzanne Trudel, Joshua Richter, Paula Rodríguez-Otero, Hun Chuah, Moshe Gatt, Eva Medvedova, Shahzad Raza, Dok Hyun Yoon, Tadao Ishida, Jeffrey V. Matous, Laura Rosiñol, Koichi Onodera, Emma Scott, Christoph Heuck, Jenny Zhang, Todd Henninger, Lisa O’Rourke, Payal Thakkar, Mariacristina Festa, Lin Huang, Jiangxiu Zhou, Mikihiro Takamoto, Lixia Pei, Jiashen Lu, Nicholas Au, Maria Krevvata, Saad Z. Usmani, and Yael C. Cohen
You can read the Full Article in NEJM.
You can find more posts featuring Robert Orlowski on OncoDaily.
